AJCN EB 2010
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cangiano, C.
Right arrow Articles by Rossi-Fanelli, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cangiano, C.
Right arrow Articles by Rossi-Fanelli, F.
Agricola
Right arrow Articles by Cangiano, C.
Right arrow Articles by Rossi-Fanelli, F.

American Journal of Clinical Nutrition, Vol 56, 863-867, Copyright © 1992 by The American Society for Clinical Nutrition, Inc

ORIGINAL RESEARCH COMMUNICATIONS

Eating behavior and adherence to dietary prescriptions in obese adult subjects treated with 5-hydroxytryptophan

C Cangiano, F Ceci, A Cascino, M Del Ben, A Laviano, M Muscaritoli, F Antonucci and F Rossi-Fanelli
3rd Department of Internal Medicine, University of Rome, La Sapienza, Italy.

Previous observations have shown that oral administration of 5- hydroxytryptophan (5-HTP) without dietary prescriptions causes anorexia, decreased food intake, and weight loss in obese subjects. To confirm these data over a longer period of observation and to verify whether adherence to dietary restriction could be improved by 5-HTP, 20 obese patients were randomly assigned to receive either 5-HTP (900 mg/d) or a placebo. The study was double-blinded and was for two consecutive 6-wk periods. No diet was prescribed during the first period, a 5040-kJ/d diet was recommended for the second. Significant weight loss was observed in 5-HTP-treated patients during both periods. A reduction in carbohydrate intake and a consistent presence of early satiety were also found. These findings together with the good tolerance observed suggest that 5-HTP may be safely used to treat obesity.


This article has been cited by other articles:


Home page
 Pharmacol. Rev.Home page
G. A. Bray and F. L. Greenway
Pharmacological Treatment of the Overweight Patient
Pharmacol. Rev., June 1, 2007; 59(2): 151 - 184.
[Full Text] [PDF]

Home page
 JAMAHome page
D. M. Bravata, L. Sanders, J. Huang, H. M. Krumholz, I. Olkin, C. D. Gardner, and D. M. Bravata
Efficacy and Safety of Low-Carbohydrate Diets: A Systematic Review
JAMA, April 9, 2003; 289(14): 1837 - 1850.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
G. A. Bray and F. L. Greenway
Current and Potential Drugs for Treatment of Obesity
Endocr. Rev., December 1, 1999; 20(6): 805 - 875.
[Abstract] [Full Text]

Home page
 Am. J. Clin. Nutr.Home page
S.-S. Yeh and M. W Schuster
Geriatric cachexia: the role of cytokines
Am. J. Clinical Nutrition, August 1, 1999; 70(2): 183 - 197.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1992 by The American Society for Nutrition